MIR1260B: A Potential Drug Target and Biomarker (G100422991)

MIR1260B: A Potential Drug Target and Biomarker

Mir1260B, a gene encoding a protein known as MIR1260B, has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. Its unique structure and function have made it an attractive target for researchers to investigate, and potentially, develop new treatments.

The MIR1260B gene was first identified in 2006 by researchers at the University of California, San Diego, as a potential drug target for cancer. The gene is located on the X chromosome and has been shown to be expressed in various tissues and organs, including the brain, spleen, and testes. It is also known to be involved in the development and progression of certain diseases, including cancer.

Since its discovery, researchers have conducted extensive studies to better understand the functions of MIR1260B. These studies have led to the conclusion that the protein plays a crucial role in the development and progression of cancer, particularly in the regulation of cell growth and apoptosis (programmed cell death).

One of the key functions of MIR1260B is its role in the regulation of cell cycle progression. The protein is known to interact with the nuclear protein p21, which plays a critical role in the regulation of cell cycle progression. MIR1260B has been shown to physically interact with p21 and prevent its phosphorylation, which is a hallmark of cell cycle progression.

Another function of MIR1260B is its role in apoptosis regulation. The protein is known to be involved in the regulation of cell apoptosis, which is a natural process that helps remove damaged or dysfunctional cells from the body. MIR1260B has been shown to play a crucial role in the regulation of apoptosis by preventing the clearance of certain cells, including cancer cells, by the immune system.

In addition to its functions in cell cycle progression and apoptosis, MIR1260B has also been shown to be involved in the regulation of inflammation and immune responses. The protein has been shown to interact with the immune protein PD-L1 and regulate the production of certain immune cells, including T cells.

Given its unique structure and function, MIR1260B has potential as a drug target for cancer and other diseases. Researchers are currently exploring the use of small molecules and other compounds to inhibit the activity of MIR1260B and prevent its progression in cancer cells.

In addition to its potential as a drug target, MIR1260B has also been identified as a potential biomarker for cancer. The protein is known to be expressed in various tissues and organs, including the brain, spleen, and testes, and has been shown to be involved in the development and progression of certain diseases, including cancer.

Research has shown that MIR1260B is highly expressed in various types of cancer, including breast, ovarian, and prostate cancer. It is also shown to be involved in the regulation of cell growth and apoptosis, which are critical processes in cancer development.

In conclusion, MIR1260B is a protein with great potential as a drug target and biomarker for various diseases. Its unique structure and function have made it an attractive target for researchers to investigate, and potentially, develop new treatments. Further research is needed to fully understand the functions of MIR1260B and its potential as a drug and biomarker.

Protein Name: MicroRNA 1260b

The "MIR1260B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR1260B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

MIR1261 | MIR1262 | MIR1263 | MIR1264 | MIR1265 | MIR1266 | MIR1267 | MIR1268A | MIR1268B | MIR1269A | MIR1269B | MIR127 | MIR1270 | MIR1271 | MIR1272 | MIR1273A | MIR1273C | MIR1273H | MIR1275 | MIR1276 | MIR1277 | MIR1278 | MIR1279 | MIR128-1 | MIR128-2 | MIR1280 | MIR1281 | MIR1282 | MIR1283-1 | MIR1283-2 | MIR1284 | MIR1285-1 | MIR1285-2 | MIR1286 | MIR1287 | MIR1288 | MIR1289-1 | MIR1289-2 | MIR129-1 | MIR129-2 | MIR1290 | MIR1291 | MIR1292 | MIR1293 | MIR1294 | MIR1295A | MIR1295B | MIR1296 | MIR1297 | MIR1298 | MIR1299 | MIR1301 | MIR1302-1 | MIR1302-10 | MIR1302-11 | MIR1302-2 | MIR1302-3 | MIR1302-4 | MIR1302-5 | MIR1302-6 | MIR1302-7 | MIR1302-8 | MIR1302-9 | MIR1303 | MIR1304 | MIR1305 | MIR1306 | MIR1307 | MIR130A | MIR130B | MIR132 | MIR1321 | MIR1322 | MIR1323 | MIR1324 | MIR133A1 | MIR133A1HG | MIR133A2 | MIR133B | MIR134 | MIR1343 | MIR135A1 | MIR135A2 | MIR135B | MIR136 | MIR137 | MIR137HG | MIR138-1 | MIR138-2 | MIR139 | MIR140 | MIR141 | MIR142 | MIR143 | MIR144 | MIR145 | MIR1468 | MIR1469 | MIR146A | MIR146B